HSBC Knock-Out MOR/ DE000HS30704 /
2024-08-22 11:20:14 AM | Chg.+0.080 | Bid2024-08-22 | Ask2024-08-22 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
49.500EUR | +0.16% | - Bid Size: - |
- Ask Size: - |
MORPHOSYS AG O.N. | 18.3803 - | 2078-12-31 | Call |
GlobeNewswire
2021-06-03
CONSTELLATION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of CNST and Encourages Investors ...
GlobeNewswire
2021-06-02
Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys
GlobeNewswire
2020-04-27
I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Mu...
GlobeNewswire
2019-04-23
Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis ...
GlobeNewswire
2019-04-23
Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis ...
GlobeNewswire
2019-01-31
Genmab Announces that the Patent Infringement Lawsuit Relating to DARZALEX® is Over
GlobeNewswire
2018-09-13
Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
GlobeNewswire
2018-09-13
Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
GlobeNewswire
2018-09-12
MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 wi...
GlobeNewswire
2018-09-12
MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 wi...
GlobeNewswire
2018-07-19
MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner
GlobeNewswire
2018-07-19
MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner
GlobeNewswire
2018-05-01
Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atop...
GlobeNewswire
2018-05-01
Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atop...
GlobeNewswire
2018-02-17
Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as lat...
GlobeNewswire
2018-02-17
Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as lat...
GlobeNewswire
2017-09-27
Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL...
GlobeNewswire
2017-09-27
Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL...